Clinical Guidelines
From the Journals

Stockholm3 Test Cuts MRIs in Prostate Screening

Blood test algorithm reduces imaging demand in organized prostate cancer testing

  • March 19, 2026

  • 3 min

Share

The Stockholm3 Study presented at the European Association of Urology Congress demonstrated that a blood-based risk test combining protein and genetic biomarkers with clinical data significantly reduced the necessity for MRI scans in prostate cancer screening. Implemented in Sweden, this approach evaluated men with PSA levels between 2 ng/mL and 3 ng/mL using the Stockholm3 test before MRI referral. Results showed a 60% reduction in MRI utilization and lower biopsy rates, underscoring the test's potential in optimizing prostate cancer screening and resource allocation.

Original Source(s)

Stockholm3 Test Cuts MRIs in Prostate Screening

  • March 19, 2026

Related Content

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission

Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria

One in 10 patients who present to the emergency room (ER) with visible hematuria die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study found that a scan administer...